Preparation method and application of tumor microenvironment response type double-targeting gene delivery system
Through guanidation modification and targeted modification of polyethyleneimine, combined with glutaraldehyde and poly(2-ethyl-2oxazoline), the precise delivery of LSD1 plasmid in the tumor microenvironment is achieved, solving the existing solutions The problems of low transfection efficiency and structural instability in the technology have significantly improved the effectiveness of anti-tumor immunotherapy.
Patent Information
- Application Number
- CN202411029916.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-07-30
AI Technical Summary
The prior art is difficult to deliver LSD1 plasmids targeting tumor cells and T cells efficiently in one system, resulting in low transfection efficiency and unstable nanoparticles in the tumor microenvironment, affecting the therapeutic effect.
Polyethyleneimine is modified through guanidation, targeting polypeptides that modify tumor cells and T cells, respectively, and crosslinking with glutaraldehyde to form a stable core-shell structure, using poly(2-ethyl-2oxazoline) As the outer shell, nanoparticles with different targeting properties are isolated under acidic conditions of the tumor microenvironment to achieve accurate delivery of plasmids.
It improves the transfection efficiency and stability of the gene delivery system, extends the retention time in vivo, enhances the infiltration and killing ability of CD8+ T cells, activates a powerful anti-tumor immune response, and significantly improves the anti-tumor treatment effect.
Smart Images

Figure CN118948801A_ABST
Abstract
Description
1. Technical Field
[0001] The present invention relates to the field of medicine, and in particular to a preparation method and application of a tumor microenvironment responsive dual-targeting gene delivery system. 2. Background Technology
[0002] CD8 + T cells are key effector cells that kill tumors. + Insufficient T cell infiltration and CD8 + T cell dysfunction will reduce its tumor killing ability. + T cell infiltration, reversal of CD8 + The exhaustion of T cells has become the key to improving anti-tumor immunotherapy. The latest research shows that knocking out gastric cancer cells or CD8 + LSD1 in T cells promotes CD8 + T cells infiltrate the tumor site and downregulate the expression of PD-L1 and PD-1, reversing the CD8 + Compared with knocking out LSD1 in one cell, it acts on both gastric cancer cells and CD8 + LSD1 in T cells better restores CD8 + The ability of T cells to kill tumors. Therefore, it is necessary to design a dual-targeted gene delivery system to deliver the LSD1 knockout plasmid (sgLSD1) to the two types of cells respectively, thereby producing a synergistic anti-tumor immunotherapy effect.
[0003] Polyethyleneimine (PEI) is the most widely studied cationic polymer gene carrier. However, it has the disadvantage of low transfection efficiency, so it needs to be modified to improve transfection efficiency. Studies have shown that guanidinyl modification is an effective method to improve transfection efficiency. In addition, in order to target T cells and tumor cells, the peptides targeting the two cells are modified on the surface of PEI separately to achieve this effect. However, how to achieve co-delivery of two plasmids in one system is a problem that needs to be solved. Aldehyde groups and primary amino groups are easy to form imine bonds. The imine bond is an acid-sensitive bond. Its structure remains stable under physiological conditions (pH = 7.4), but it will be hydrolyzed and broken under tumor microenvironment conditions (pH = 6.5). Therefore, the aldehyde groups at both ends of glutaraldehyde and the amino groups on the polyethyleneimine in the nanoparticles form imine bonds to cross-link two nanoparticles with different targeting properties. However, after cross-linking, the nanoparticles still have strong positive charge, are easy to non-specifically bind to serum proteins, and are quickly cleared from the blood, which seriously hinders their further application in vivo. Studies have shown that poly(2-ethyl-2-oxazoline) is negatively charged under physiological conditions, but undergoes protonation at pH 6.5 to convert to a positive charge. Using PEOz as the shell of the nanosystem is expected to solve the above problems. In summary, targeted knockout of LSD1 in tumor cells and T cells, respectively, can better restore CD8 + The ability of T cells to kill tumors and achieve excellent anti-tumor immunotherapy effects is a technical problem that urgently needs to be solved. III. Summary of the invention
[0004] In view of the above situation, in order to solve the defects of the prior art, the purpose of the present invention is to provide a preparation method and application of a tumor microenvironment responsive dual-targeting gene delivery system, which can effectively solve the problem of in situ reprogramming of tumor cells and T cells, improve the anti-tumor immunotherapy effect, and ensure the cancer treatment effect.
[0005] The technical solution provided by the present invention is to react polyethyleneimine and 1H-pyrazole-1-carboxamidine hydrochloride at room temperature, and then respectively modify the polypeptide targeting tumor cells and the polypeptide targeting T cells through amide reaction, and then condense with sgLSD1 plasmid respectively, and then physically mix, add glutaraldehyde for cross-linking, and finally wrap poly (2-ethyl-2-oxazoline) in the outer layer to form a stable core-shell structure, so as to obtain a tumor microenvironment responsive dual-targeting gene delivery system, which specifically includes the following steps:
[0006] 1) Preparation of guanidinized polyethyleneimine (GPEI)
[0007] Take 1-6g of polyethyleneimine and dissolve it in 3-8mL of solvent, add it to a three-necked flask and protect it with nitrogen, take 1-6g of 1H-pyrazole-1-carboxamidine hydrochloride and dissolve it in 5mL of solvent, add it to the polyethyleneimine solution, stir and react at room temperature for 10-35min, add 1-6g of triethylamine to the above mixed solution, stir at room temperature for 24h, put the solution after the reaction into a 500Da dialysis bag, dialyze for 48h, and then freeze-dry the product to obtain guanidinium polyethyleneimine (GPEI);
[0008] 2) Preparation of T cell targeting vector (T-GPEI)
[0009] 10-60 mg of T cell targeting peptide was dissolved in 1-6 mL of solvent and placed in a three-necked flask, which was filled with nitrogen for protection. 3-8 mg of N-hydroxysuccinimide and 6-11 mg of (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) were dissolved in 1 mL of solvent and added to the above three-necked flask, and stirred at room temperature for 12 h. 20-70 mg of guanidated polyethyleneimine was added to 2-7 mL of solvent to fully dissolve, and added to the three-necked flask. After stirring at room temperature for 24 h, it was placed in a 1500 Da dialysis bag and dialyzed for 48 h to fully remove unreacted substances. The dialyzed product was freeze-dried for 48 h to obtain T cell targeting peptide-modified guanidated polyethyleneimine (T-GPEI);
[0010] The T cell targeting peptide is a polypeptide chain containing the sequence AKMGEGGWGANDY;
[0011] 3) Preparation of tumor cell targeting vector (M-GPEI)
[0012] Take 20-70 mg of tumor cell targeting peptide and dissolve it in 3 mL of solvent, then add it to a three-necked flask and fill it with nitrogen for protection. Then add a solvent solution containing 3-8 mg of N-hydroxysuccinimide and 8-13 mg of (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) to the three-necked flask, and activate the carboxyl group at room temperature for 12 hours. Finally, add a solvent solution containing 30-80 mg of guanidinized polyethyleneimine to the above reaction system, react at room temperature for 24 hours, and the solution after the reaction is placed in a 2500Da dialysis bag for 48 hours. The product is freeze-dried for 48 hours to obtain guanidinized polyethyleneimine (M-GPEI) modified with tumor cell targeting peptide;
[0013] The tumor cell targeting peptide is a polypeptide chain containing the sequence SGQYASYHCWCWRDPGRSGGSK;
[0014] 4) Prepare T cell targeting vector solution and tumor cell targeting vector solution (TG, MG)
[0015] Take 30-80 mg of the T cell targeting vector prepared in step 2) and the tumor cell targeting vector prepared in step 3) and dissolve them in 40 mL of solvent respectively, adjust the pH of the above two solutions to 7.4 with 1 mol / L NaOH solution, then transfer them to a 50 mL volumetric flask, dilute to 50 mL with solvent, shake well to obtain a T cell targeting vector solution and a tumor cell targeting vector solution with a concentration of 1 mg / mL, and filter the prepared solutions with a 0.22 μm microporous filter membrane;
[0016] 5) Synthesize T cell targeting vector / plasmid complexes and tumor cell targeting vector / plasmid complexes (TG / sg, MG / sg)
[0017] Take two portions of plasmid, 4-9 mL and 7-12 mg respectively, dilute them to 0.01 mg / mL with a solvent, take 50 mL of the T cell targeting vector solution and the tumor cell targeting vector solution prepared in step 4), dilute them to 0.1 mg / mL with a solvent, add them dropwise to the diluted plasmid solution, shake and mix continuously, and let stand at room temperature for 10 min to obtain a T cell targeting vector / plasmid complex and a tumor cell targeting vector / plasmid complex;
[0018] 6) Tumor microenvironment-responsive dual-targeted gene delivery system (P@cPG / sg)
[0019] Take the T cell targeting vector / plasmid complex and the tumor cell targeting vector / plasmid complex in step 5), mix the two solutions in equal amounts, add 170-220 mL of 25% glutaraldehyde solution, mix well and let stand at room temperature for 5 minutes, take 30-80 mg of poly(2-ethyl-2-oxazoline) and prepare it with a solvent to a solution with a concentration of 1 mg / mL, measure 300-800 mL and add it dropwise to the above solution, let stand at room temperature for 10 minutes, and obtain a tumor microenvironment responsive dual-targeting gene delivery system.
[0020] The solvent in steps 1)-6) is one of ultrapure water, PBS buffer with pH=7.4, and formamide.
[0021] Application of the tumor microenvironment responsive dual-targeted gene delivery system of the present invention in the preparation of anti-tumor drugs.
[0022] Application of the tumor microenvironment responsive dual-targeted gene delivery system of the present invention in the preparation of highly efficient gene delivery.
[0023] The invention is easy to operate, the method is stable and reliable, the prepared dual-targeted gene delivery system has good biocompatibility and long retention time, and can be used in situ to reprogram tumor cells and T cells, increase CD8 +It has multiple functions such as T cell infiltration and reversal of T cell exhaustion, which can effectively improve the efficiency of in situ programming of tumor cells and T cells and efficiently activate anti-tumor immune response. It is an innovation in tumor treatment drugs with huge economic and social benefits. IV. Description of the drawings
[0024] Figure 1 TEM images of P@cPG / sg prepared in the present invention at pH = 7.4 and pH = 6.5.
[0025] Figure 2 AB Western Blot detection of MFC cells (1, 2) and CD8 + LSD1 expression in T cells (1, 3) before and after transfection.
[0026] Figure 3 CD8 + Expression of LSD1 in T cells.
[0027] Figure 4 These are live cell imaging images of the untreated group and the P@cPG / sg group of the present invention.
[0028] Figure 5 These are in vivo fluorescence images of mice taken at different drug administration time points using the in vivo imaging of the present invention.
[0029] Figure 6 The flow cytometry method was used to investigate CD8 + Uptake of the formulation by T cells (A) and MFC cells (B).
[0030] Figure 7 The flow cytometry method of the present invention is used to detect tumor cells (A) and CD8 + Expression of LSD1 in T cells (B).
[0031] Figure 8 The flow cytometry method of the present invention is used to detect CD8 + T cell infiltration (A) and its function-related indicators (BD). V. Specific implementation methods
[0032] The specific implementation modes of the present invention are further described in detail below in conjunction with the embodiments.
[0033] Example 1
[0034] The present invention, when implemented, specifically comprises the following steps:
[0035] 1) Preparation of guanidinized polyethyleneimine
[0036] Take 1g of polyethyleneimine and dissolve it in 3mL of ultrapure water, add it into a three-necked flask and fill it with nitrogen protection, take 1g of 1H-pyrazole-1-carboxamidine hydrochloride and dissolve it in 5mL of ultrapure water, add it into the polyethyleneimine solution, stir at room temperature for 10min, add 1g of triethylamine into the above mixed solution, stir at room temperature for 24h, put the solution after the reaction into a 500Da dialysis bag, dialyze for 48h, and then freeze-dry the product to obtain guanidinium polyethyleneimine;
[0037] 2) Preparation of T cell targeting vector
[0038] Take 10 mg of T cell targeting peptide, dissolve it in 1 mL of formamide and put it into a three-necked flask, and fill it with nitrogen for protection. Take 3 mg of N-hydroxysuccinimide and 6 mg of (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) and dissolve it in 1 mL of formamide and add it to the above three-necked flask, stir at room temperature for 12 hours, take 20 mg of guanidinized polyethyleneimine prepared in step 1) and add 2 mL of formamide to fully dissolve it, add it to the three-necked flask, stir at room temperature for 24 hours, then put it into a 1500Da dialysis bag and dialyze it for 48 hours to fully remove unreacted substances. The dialyzed product is freeze-dried for 48 hours to obtain a T cell targeting vector;
[0039] 3) Preparation of tumor cell targeting vector
[0040] Take 20 mg of tumor cell targeting peptide and dissolve it in 3 mL of formamide, then add it to a three-necked flask and fill it with nitrogen for protection. Then add a formamide solution containing 3 mg of N-hydroxysuccinimide and 8 mg of (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) to the three-necked flask, activate the carboxyl group at room temperature for 12 hours, and finally add a formamide solution containing 30 mg of guanidinized polyethyleneimine to the above reaction system, react at room temperature for 24 hours, and the solution after the reaction is placed in a 2500Da dialysis bag for 48 hours. The product is freeze-dried for 48 hours to obtain a tumor cell targeting vector;
[0041] 4) Prepare T cell targeting vector solution and tumor cell targeting vector solution
[0042] Take 30 mg of the T cell targeting vector prepared in step 2) and the tumor cell targeting vector prepared in step 3) and dissolve them in 40 mL of ultrapure water respectively, adjust the pH of the two solutions to 7.4 with 1 mol / L NaOH solution, then transfer them to a 50 mL volumetric flask, make up to 50 mL with ultrapure water, shake well to obtain two vector solutions with a concentration of 1 mg / mL, and filter the prepared solutions with a 0.22 μm microporous filter membrane;
[0043] 5) Synthesis of T cell targeting vector / plasmid complexes and tumor cell targeting vector / plasmid complexes
[0044] Take two portions of 4 mL and 7 mg of plasmid, respectively, dilute them to 0.01 mg / mL with ultrapure water, take 50 mL of the T cell targeting vector solution and tumor cell targeting vector solution prepared in step 4) (corresponding to 4 mL and 7 mg of plasmid, respectively), dilute them to 0.1 mg / mL with ultrapure water, add them dropwise to the diluted plasmid solution, shake and mix continuously, and let stand at room temperature for 10 min to obtain T cell targeting vector / plasmid complex and tumor cell targeting vector / plasmid complex;
[0045] 6) Tumor microenvironment-responsive dual-targeted gene delivery system
[0046] Take the T cell targeting vector / plasmid complex and the tumor cell targeting vector / plasmid complex prepared in step 5), mix the two solutions in equal amounts, add 170 mL of 25% glutaraldehyde solution, mix well and let stand at room temperature for 5 minutes, take 30 mg of poly(2-ethyl-2-oxazoline) and prepare it with ultrapure water to a solution with a concentration of 1 mg / mL, measure 500 mL and add it dropwise to the above solution, let stand at room temperature for 10 minutes, and obtain a tumor microenvironment responsive dual-targeting gene delivery system.
[0047] Example 2
[0048] The present invention may further include the following steps when implemented:
[0049] 1) Preparation of guanidinized polyethyleneimine
[0050] Take 2g of polyethyleneimine and dissolve it in 4mL of ultrapure water, add it to a three-necked flask and fill it with nitrogen protection, take 2g of 1H-pyrazole-1-carboxamidine hydrochloride and dissolve it in 5mL of ultrapure water, add it to the polyethyleneimine solution, stir at room temperature for 15min, add 2g of triethylamine to the above mixed solution, stir at room temperature for 24h, put the solution after the reaction into a 500Da dialysis bag, dialyze for 48h, and then freeze-dry the product to obtain guanidinium polyethyleneimine;
[0051] 2) Preparation of T cell targeting vector
[0052] Take 20 mg of T cell targeting peptide, dissolve it in 2 mL of formamide and put it into a three-necked flask, fill it with nitrogen for protection, take 4 mg of N-hydroxysuccinimide and 7 mg of (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) and dissolve it in 2 mL of formamide and add it to the above three-necked flask, stir at room temperature for 12 hours, take 30 mg of guanidinium polyethyleneimine prepared in step 1), add 3 mL of formamide to fully dissolve, add it to the three-necked flask, stir at room temperature for reaction for 24 hours, then put it into a 1500Da dialysis bag and dialyze it for 48 hours to fully remove unreacted substances, and freeze-dry the dialyzed product for 48 hours to obtain a T cell targeting vector;
[0053] 3) Preparation of tumor cell targeting vector
[0054] 30 mg of tumor cell targeting peptide was dissolved in 3 mL of formamide, then added to a three-necked flask and filled with nitrogen for protection, then a formamide solution containing 5 mg of N-hydroxysuccinimide and 9 mg of (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) was added to the three-necked flask, and the carboxyl group was activated at room temperature for 12 hours. Finally, a formamide solution containing 40 mg of guanidinized polyethyleneimine was added to the above reaction system, and the reaction was carried out at room temperature for 24 hours. The solution after the reaction was placed in a 2500Da dialysis bag for 48 hours, and the product was freeze-dried for 48 hours to obtain a tumor cell targeting vector;
[0055] 4) Prepare T cell targeting vector solution and tumor cell targeting vector solution
[0056] Take 40 mg of the T cell targeting vector prepared in step 2) and the tumor cell targeting vector prepared in step 3) and dissolve them in 50 mL of ultrapure water respectively, adjust the pH of the two solutions to 7.4 with 1 mol / L NaOH solution, then transfer them to a 50 mL volumetric flask, make up to 50 mL with ultrapure water, and shake well to obtain a T cell targeting vector solution and a tumor cell targeting vector solution with a concentration of 1 mg / mL, and filter the prepared solutions with a 0.22 μm microporous filter membrane;
[0057] 5) Synthesis of T cell targeting vector / plasmid complexes and tumor cell targeting vector / plasmid complexes
[0058] Take two portions of 5 mL and 8 mg of plasmid respectively, dilute them to 0.01 mg / mL with ultrapure water, take 50 mL of the T cell targeting vector solution and tumor cell targeting vector solution prepared in step 4), dilute them to 0.1 mg / mL with ultrapure water, add them dropwise to the diluted plasmid solution, shake and mix continuously, and stand at room temperature for 10 min to obtain the T cell targeting vector / plasmid complex and the tumor cell targeting vector / plasmid complex;
[0059] 6) Tumor microenvironment-responsive dual-targeted gene delivery system
[0060] Take the T cell targeting vector / plasmid complex and the tumor cell targeting vector / plasmid complex prepared in step 5), mix the two solutions in equal amounts, add 180 mL of 25% glutaraldehyde solution, mix well and let stand at room temperature for 5 minutes, take 40 mg of poly(2-ethyl-2-oxazoline) and prepare it with ultrapure water to a solution with a concentration of 1 mg / mL, measure 600 mL and add it dropwise to the above solution, let stand at room temperature for 10 minutes, and obtain a tumor microenvironment responsive dual-targeting gene delivery system.
[0061] Example 3
[0062] The present invention may further include the following steps when implemented:
[0063] 1) Preparation of guanidinized polyethyleneimine
[0064] Take 3g of polyethyleneimine and dissolve it in 5mL of ultrapure water, add it to a three-necked flask and fill it with nitrogen. Take 3g of 1H-pyrazole-1-carboxamidine hydrochloride and dissolve it in 5mL of ultrapure water, add it to the polyethyleneimine solution, stir at room temperature for 20min, add 3g of triethylamine to the mixed solution, and stir at room temperature for 24h. The solution after the reaction is loaded into a 500Da dialysis bag, and the product is lyophilized after dialysis for 48h to obtain guanidinium polyethyleneimine;
[0065] 2) Preparation of T cell targeting vector
[0066] Take 30 mg of T cell targeting peptide, dissolve it in 3 mL of formamide and put it into a three-necked flask, and fill it with nitrogen for protection. Take 5 mg of N-hydroxysuccinimide and 10 mg of (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) and dissolve it in 3 mL of formamide and add it to the above three-necked flask, stir at room temperature for 12 hours, take 40 mg of guanidinized polyethyleneimine prepared in step 1) and add 4 mL of formamide to fully dissolve it, add it to the three-necked flask, stir at room temperature for 24 hours, then put it into a 1500Da dialysis bag and dialyze it for 48 hours to fully remove unreacted substances. The dialyzed product is freeze-dried for 48 hours to obtain a T cell targeting vector;
[0067] 3) Preparation of tumor cell targeting vector
[0068] 40 mg of tumor cell targeting peptide was dissolved in 3 mL of formamide, and then the solution was added to a three-necked flask and filled with nitrogen for protection. Then, a formamide solution containing 7 mg of N-hydroxysuccinimide and 10 mg of (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) was added to the three-necked flask, and the carboxyl group was activated at room temperature for 12 hours. Finally, a formamide solution containing 50 mg of guanidinized polyethyleneimine was added to the above reaction system, and the reaction was carried out at room temperature for 24 hours. The solution after the reaction was placed in a 2500Da dialysis bag for 48 hours, and the product was freeze-dried for 48 hours to obtain a tumor cell targeting vector;
[0069] 4) Prepare T cell targeting vector solution and tumor cell targeting vector solution
[0070] Take 50 mg of the T cell targeting vector prepared in step 2) and the tumor cell targeting vector prepared in step 3) and dissolve them in 50 mL of ultrapure water respectively, adjust the pH of the two solutions to 7.4 with 1 mol / L NaOH solution, then transfer them to a 50 mL volumetric flask, make up to 50 mL with ultrapure water, shake well to obtain a T cell targeting vector solution and a tumor cell targeting vector solution, and filter the prepared solutions with a 0.22 μm microporous filter membrane;
[0071] 5) Synthesis of T cell targeting vector / plasmid complexes and tumor cell targeting vector / plasmid complexes
[0072] Take two portions of 6 mL and 9 mg of plasmid respectively, dilute them to 0.01 mg / mL with ultrapure water, take 50 mL of the T cell targeting vector solution and tumor cell targeting vector solution prepared in step 4), dilute them to 0.1 mg / mL with ultrapure water, add them dropwise to the diluted plasmid solution, shake and mix continuously, and let stand at room temperature for 10 min to obtain T cell targeting vector / plasmid complex and tumor cell targeting vector / plasmid complex;
[0073] 6) Tumor microenvironment-responsive dual-targeted gene delivery system
[0074] Take the T cell targeting vector / plasmid complex and the tumor cell targeting vector / plasmid complex in step 5), mix the two solutions in equal amounts, add 190 mL of 25% glutaraldehyde solution, mix well and let stand at room temperature for 5 minutes, take 50 mg of poly(2-ethyl-2-oxazoline) and prepare it with ultrapure water to a solution with a concentration of 1 mg / mL, measure 700 mL and add it dropwise to the above solution, let stand at room temperature for 10 minutes, and obtain a tumor microenvironment responsive dual-targeting gene delivery system.
[0075] Example 4
[0076] The present invention may further include the following steps when implemented:
[0077] 1) Preparation of guanylated polyethyleneimine: 4 g polyethyleneimine was dissolved in 6 mL ultrapure water, added to a three-necked flask and filled with nitrogen for protection, 4 g 1H-pyrazole-1-carboxamidine hydrochloride was dissolved in 5 mL ultrapure water, added to the polyethyleneimine solution, stirred at room temperature for 25 min, 4 g triethylamine was added to the mixed solution, and stirred at room temperature for 24 h. The reacted solution was placed in a 500 Da dialysis bag, and the product was lyophilized after dialysis for 48 h to obtain guanylated polyethyleneimine;
[0078] 2) Preparation of T cell targeting vector
[0079] 40 mg of T cell targeting peptide was dissolved in 4 mL of formamide and placed in a three-necked flask, which was filled with nitrogen for protection. 6 mg of N-hydroxysuccinimide and 9 mg of (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) were dissolved in 3 mL of formamide and added to the above three-necked flask, and stirred at room temperature for 12 h. 50 mg of guanidated polyethyleneimine prepared in step 1) was added to 5 mL of formamide to fully dissolve, and then added to the three-necked flask. After stirring at room temperature for 24 h, it was placed in a 1500 Da dialysis bag and dialyzed for 48 h to fully remove unreacted substances. The dialyzed product was freeze-dried for 48 h to obtain a T cell targeting vector.
[0080] 3) Preparation of tumor cell targeting vector
[0081] 50 mg of tumor cell targeting peptide was dissolved in 4 mL of formamide, and then the solution was added to a three-necked flask and filled with nitrogen for protection. Then, a formamide solution containing 7 mg of N-hydroxysuccinimide and 11 mg of (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) was added to the three-necked flask, and the carboxyl group was activated at room temperature for 12 hours. Finally, a formamide solution containing 60 mg of guanidinized polyethyleneimine was added to the above reaction system, and the reaction was carried out at room temperature for 24 hours. The solution after the reaction was placed in a 2500Da dialysis bag for 48 hours, and the product was freeze-dried for 48 hours to obtain a tumor cell targeting vector.
[0082] 4) Prepare T cell targeting vector solution and tumor cell targeting vector solution
[0083] Take 60 mg of the T cell targeting vector prepared in step 2) and the tumor cell targeting vector prepared in step 3) and dissolve them in 50 mL of ultrapure water respectively, adjust the pH of the two solutions to 7.4 with 1 mol / L NaOH solution, then transfer them to a 50 mL volumetric flask, make up to 50 mL with ultrapure water, and shake well to obtain a T cell targeting vector solution and a tumor cell targeting vector solution with a concentration of 1 mg / mL. Filter the prepared solutions with a 0.22 μm microporous filter membrane;
[0084] 5) Synthesis of T cell targeting vector / plasmid complexes and tumor cell targeting vector / plasmid complexes
[0085] Take two portions of 7 mL and 10 mg of plasmid respectively, dilute them to 0.01 mg / mL with ultrapure water, take 50 mL of the T cell targeting vector solution and tumor cell targeting vector solution prepared in step 4), dilute them to 0.1 mg / mL with ultrapure water, add them dropwise to the diluted plasmid solution, shake and mix continuously, and stand at room temperature for 10 min to obtain the T cell targeting vector / plasmid complex and the tumor cell targeting vector / plasmid complex;
[0086] 6) Tumor microenvironment-responsive dual-targeted gene delivery system
[0087] Take the T cell targeting vector / plasmid complex and the tumor cell targeting vector / plasmid complex prepared in step 5), mix the two solutions in equal amounts, add 200 mL of 25% glutaraldehyde solution, mix well and let stand at room temperature for 5 minutes, take 60 mg of poly(2-ethyl-2-oxazoline) and prepare it with ultrapure water to a solution with a concentration of 1 mg / mL, measure 700 mL and add it dropwise to the above solution, let stand at room temperature for 10 minutes, and obtain a tumor microenvironment responsive dual-targeting gene delivery system.
[0088] Example 5
[0089] The present invention may further include the following steps when implemented:
[0090] 1) Preparation of guanidinized polyethyleneimine
[0091] Take 5g of polyethyleneimine and dissolve it in 7mL of ultrapure water, add it to a three-necked flask and fill it with nitrogen protection, take 5g of 1H-pyrazole-1-carboxamidine hydrochloride and dissolve it in 5mL of ultrapure water, add it to the polyethyleneimine solution, stir at room temperature for 30min, add 5g of triethylamine to the mixed solution, stir at room temperature for 24h, put the solution after the reaction into a 500Da dialysis bag, dialyze for 48h, and then freeze-dry the product to obtain guanidinium polyethyleneimine;
[0092] 2) Preparation of T cell targeting vector
[0093] 50 mg of T cell targeting peptide was dissolved in 5 mL of formamide and placed in a three-necked flask, which was filled with nitrogen for protection. 7 mg of N-hydroxysuccinimide and 10 mg of (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) were dissolved in 3 mL of formamide and added to the above three-necked flask, and stirred at room temperature for 12 h. 60 mg of guanidated polyethyleneimine prepared in step 1) was added to 6 mL of formamide to fully dissolve, and then added to the three-necked flask. After stirring at room temperature for 24 h, it was placed in a 1500 Da dialysis bag and dialyzed for 48 h to fully remove unreacted substances. The dialyzed product was freeze-dried for 48 h to obtain a T cell targeting vector.
[0094] 3) Preparation of tumor cell targeting vector
[0095] 60 mg of tumor cell targeting peptide was dissolved in 4 mL of formamide, and then the solution was added to a three-necked flask and filled with nitrogen for protection. Then, a formamide solution containing 7 mg of N-hydroxysuccinimide and 12 mg of (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) was added to the three-necked flask, and the carboxyl group was activated at room temperature for 12 hours. Finally, a formamide solution containing 70 mg of guanidinized polyethyleneimine was added to the above reaction system, and the reaction was carried out at room temperature for 24 hours. The solution after the reaction was placed in a 2500Da dialysis bag for 48 hours, and the product was freeze-dried for 48 hours to obtain a tumor cell targeting vector.
[0096] 4) Prepare T cell targeting vector solution and tumor cell targeting vector solution
[0097] Take 70 mg of the T cell targeting vector prepared in step 2) and the tumor cell targeting vector prepared in step 3) and dissolve them in 50 mL of ultrapure water respectively, adjust the pH of the two solutions to 7.4 with 1 mol / L NaOH solution, then transfer them to a 50 mL volumetric flask, make up to 50 mL with ultrapure water, and shake well to obtain a T cell targeting vector solution and a tumor cell targeting vector solution with a concentration of 1 mg / mL. Filter the prepared solutions with a 0.22 μm microporous filter membrane;
[0098] 5) Synthesis of T cell targeting vector / plasmid complexes and tumor cell targeting vector / plasmid complexes
[0099] Take two portions of 8 mL and 11 mg of plasmid respectively, dilute them to 0.01 mg / mL with ultrapure water, take 50 mL of the T cell targeting vector solution and tumor cell targeting vector solution prepared in step 4), dilute them to 0.1 mg / mL with ultrapure water, add them dropwise to the diluted plasmid solution, shake and mix continuously, and let stand at room temperature for 10 min to obtain T cell targeting vector / plasmid complex and tumor cell targeting vector / plasmid complex;
[0100] 6) Tumor microenvironment-responsive dual-targeted gene delivery system
[0101] Take the T cell targeting vector / plasmid complex and the tumor cell targeting vector / plasmid complex prepared in step 5), mix the two solutions in equal amounts, add 210 mL of 25% glutaraldehyde solution, mix well and let stand at room temperature for 5 minutes, take 70 mg of poly(2-ethyl-2-oxazoline) and prepare it with ultrapure water to a solution with a concentration of 1 mg / mL, measure 700 mL and add it dropwise to the above solution, let stand at room temperature for 10 minutes, and obtain a tumor microenvironment responsive dual-targeting gene delivery system.
[0102] Example 6
[0103] The present invention may further include the following steps when implemented:
[0104] 1) Preparation of guanidinized polyethyleneimine
[0105] Take 6g of polyethyleneimine and dissolve it in 8mL of ultrapure water, add it into a three-necked flask and fill it with nitrogen protection, take 6g of 1H-pyrazole-1-carboxamidine hydrochloride and dissolve it in 5mL of ultrapure water, add it into the polyethyleneimine solution, stir at room temperature for 35min, add 6g of triethylamine into the above mixed solution, stir at room temperature for 24h, put the solution after the reaction into a 500Da dialysis bag, dialyze for 48h, and then freeze-dry the product to obtain guanidinium polyethyleneimine;
[0106] 2) Preparation of T cell targeting vector
[0107] 60 mg of T cell targeting peptide was dissolved in 6 mL of formamide and placed in a three-necked flask, which was filled with nitrogen for protection. 8 mg of N-hydroxysuccinimide and 11 mg of (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) were dissolved in 3 mL of formamide and added to the above three-necked flask, and stirred at room temperature for 12 h. 70 mg of guanidated polyethyleneimine prepared in step 1) was added to 7 mL of formamide to fully dissolve, and then added to the three-necked flask. After stirring at room temperature for 24 h, it was placed in a 1500 Da dialysis bag and dialyzed for 48 h to fully remove unreacted substances. The dialyzed product was freeze-dried for 48 h to obtain a T cell targeting vector.
[0108] 3) Preparation of tumor cell targeting vector
[0109] 70 mg of tumor cell targeting peptide was dissolved in 4 mL of formamide, and then the solution was added to a three-necked flask and filled with nitrogen for protection. Then, a formamide solution containing 8 mg of N-hydroxysuccinimide and 13 mg of (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) was added to the three-necked flask, and the carboxyl group was activated at room temperature for 12 hours. Finally, a formamide solution containing 80 mg of guanidinized polyethyleneimine was added to the above reaction system, and the reaction was carried out at room temperature for 24 hours. The solution after the reaction was placed in a 2500Da dialysis bag for 48 hours, and the product was freeze-dried for 48 hours to obtain a tumor cell targeting vector;
[0110] 4) Prepare T cell targeting vector solution and tumor cell targeting vector solution
[0111] Take 80 mg of the T cell targeting vector prepared in step 2) and the tumor cell targeting vector prepared in step 3) and dissolve them in 50 mL of ultrapure water respectively, adjust the pH of the two solutions to 7.4 with 1 mol / L NaOH solution, then transfer them to a 50 mL volumetric flask, make up to 50 mL with ultrapure water, and shake well to obtain a T cell targeting vector solution and a tumor cell targeting vector solution with a concentration of 1 mg / mL. Filter the prepared solutions with a 0.22 μm microporous filter membrane;
[0112] 5) Synthesis of T cell targeting vector / plasmid complexes and tumor cell targeting vector / plasmid complexes
[0113] Take two portions of 9 mL and 12 mg of plasmid respectively, dilute them to 0.01 mg / mL with ultrapure water, take 50 mL of the T cell targeting vector solution and tumor cell targeting vector solution prepared in step 4), dilute them to 0.1 mg / mL with ultrapure water, add them dropwise to the diluted plasmid solution, shake and mix continuously, and let stand at room temperature for 10 min to obtain T cell targeting vector / plasmid complex and tumor cell targeting vector / plasmid complex;
[0114] 6) Tumor microenvironment-responsive dual-targeted gene delivery system
[0115] Take the T cell targeting vector / plasmid complex and the tumor cell targeting vector / plasmid complex prepared in step 5), mix the two solutions in equal amounts, add 220 mL of 25% glutaraldehyde solution, mix well and let stand at room temperature for 5 minutes, take 80 mg of poly(2-ethyl-2-oxazoline) and prepare it with ultrapure water to a solution with a concentration of 1 mg / mL, measure 700 mL and add it dropwise to the above solution, let stand at room temperature for 10 minutes, and obtain a tumor microenvironment responsive dual-targeting gene delivery system.
[0116] The tumor microenvironment responsive dual-targeted gene delivery system prepared in the above-mentioned Examples 1-6 and other Examples of the present invention can play multiple functions in tumor treatment, such as targeting tumors, improving the effect of anti-tumor immunotherapy, and reversing T cell exhaustion. It is effectively used in the preparation of anti-tumor drugs, and is used in the preparation of anti-tumor drugs (injections), in the preparation of drugs that reduce the PD-1 / PD-L1 axis, and in the preparation of immunotherapy drugs based on in situ reprogramming of tumor cells and T cells.
[0117] The present invention uses 1800Da polyethyleneimine with less toxicity to condense a plasmid that knocks out LSD1, but it has the disadvantage of low transfection efficiency, so it needs to be modified and transformed to improve its transfection efficiency. In view of this, 1800Da polyethyleneimine is guanidinized, which improves the transfection efficiency of polyethyleneimine in multiple ways of condensation plasmid, cell uptake, lysosomal escape and plasmid nuclear entry. In order to achieve the cell selectivity of the vector, two polypeptides targeting tumor cells (SGQYASYHCWCWRDPGRSGGSK) and T cells (AKMGEGGWGANDY) are modified respectively, and two small-size nanoparticles with different targeting are obtained after condensation of the plasmid. In order to deliver it to the tumor site at the same time and not affect the subsequent separate targeting of two cells, glutaraldehyde is proposed to be used as a connecting arm. The aldehyde group and the primary amino group are easy to form an imine bond. The imine bond is an acid-sensitive bond. Its structure remains stable under physiological conditions (pH = 7.4), but it will be hydrolyzed and broken under tumor microenvironment conditions (pH = 6.5). Therefore, the aldehyde groups at both ends and the amino groups on the polyethyleneimine in the nanoparticles are used to form an imine bond to cross-link two nanoparticles with different targeting properties. After cross-linking, the nanoparticles still have a strong positive charge, are easy to non-specifically bind to serum proteins, and are quickly cleared from the blood, which seriously hinders its further application in vivo. In order to shield the positive charge, the present invention selects to use poly (2-ethyl-2-oxazoline) as the outer shell, which is negatively charged under physiological conditions, but can be protonated and converted to positive charge at pH = 6.5, thereby generating charge repulsion with the inner core to achieve the effect of falling off from the surface of the nanoparticle. When the dual-targeted gene delivery system reaches the tumor microenvironment, the outer layer (2-ethyl-2-oxazoline) reverses from negative charge to positive charge, and the inner core with positive charge is repelled and detached. At the same time, the carbon-nitrogen double bond in the cross-linked core is broken in response to acid, and the two nanoparticles with different targeting properties are separated. Under the modification of the target head and guanidine group, the LSD1 knockout plasmid can be efficiently and accurately delivered to the tumor cells and T cell nuclei, knocking out LSD1 in both cells, thereby increasing CD8 + T cell infiltration, restoration of CD8 + The proliferation and differentiation ability of T cells, reducing the expression of PD-L1 and PD-1, activating CD8 + T cell killing response stimulates a powerful anti-tumor immune response.
[0118] The gene delivery vector prepared by the present invention has a simple synthesis method. The dual-targeted nano gene delivery system can respond to the acidic environment of the tumor microenvironment. The poly (2-ethyl-2-oxazoline) shell is reversed from a negative charge to a positive charge, and generates charge repulsion with the positively charged core, and falls off from the surface of the nanoparticle. The cross-linked core also responds to the acidic environment at the same time, and the nitrogen-carbon double bond breaks and disintegrates into nanoparticles with different targeting properties, respectively accurately targeting tumor cells and T cells and knocking out LSD1 in the two cells, thereby increasing CD8+ T cells infiltrate and activate their killing response, exerting a powerful anti-tumor immunotherapy, and repeated multiple tests have achieved consistent or similar results. Taking Example 2 as an example, the relevant test data are as follows:
[0119] 1. Characterization of the tumor microenvironment-responsive dual-targeted gene delivery system
[0120] 1. Determination of the guanidine grafting rate in guanylated polyethyleneimine;
[0121] Appropriate amounts of polyethyleneimine before and after guanidine modification were weighed, and the content information of the four elements C, N, H, and S of the two analytes was obtained by an organic element analyzer using a high temperature combustion method. The grafting rate was calculated to be about 28.9%.
[0122] 2. Determination of particle size and potential of tumor microenvironment-responsive dual-targeted gene delivery system;
[0123] Appropriate amounts of dual-targeted gene delivery system (pH=7.4) and dual-targeted gene delivery system (pH=6.5) were taken, and their hydrated particle sizes and potentials were measured using a laser nanoparticle size analyzer to be 200 nm and 60 nm, respectively, and the potentials were -5 mV and 35 mV.
[0124] 3. Transmission electron microscopy characterization of tumor microenvironment responsive dual-targeted gene delivery system:
[0125] Take the complex at pH = 7.4 and pH = 6.5, add 1 drop on a common carbon support film, wait for the liquid to evaporate, and take a picture with a transmission electron microscope. Figure 1 As shown in AB, it can be seen that the dual-targeted gene delivery system successfully disintegrated into small-sized nanoparticles before cross-linking under the acidic conditions of the tumor microenvironment.
[0126] 2. In vitro targeting of the tumor microenvironment-responsive dual-targeting gene delivery system
[0127] 1. Detection of LSD1 knockout in tumor cells by western blot technology:
[0128] MFC gastric cancer cells were cultured, and tumor cell protein samples were extracted 48 hours after administration. The expression of LSD1 protein was detected by western blot. Figure 2 AB results showed that the dual-targeted gene delivery system effectively knocked out LSD1 in tumor cells.
[0129] 2. Detection of LSD1 knockout in T cells by flow cytometry:
[0130] T cells were extracted from 615 mice, plated and collected 48 hours after administration, incubated with antibody working solution on ice, washed, filtered and loaded into flow tubes for detection by flow cytometry. The results showed that the dual-targeted gene delivery system effectively reduced the expression of LSD1-positive T cells ( Figure 3 ).
[0131] 3. Detection of T cell function recovery in the co-culture system by live cell imaging:
[0132] The extracted T cells were co-cultured with MFC gastric cancer cells, and the viability of tumor cells in the co-culture system was detected by live cell imaging 48 hours after administration. Figure 4 The results showed that after treatment with the dual-targeted gene delivery system, tumor cells were significantly killed, indicating that this group of T cells had the best recovery of function.
[0133] 3. In vivo targeting of the tumor microenvironment-responsive dual-targeting gene delivery system
[0134] 1. In vivo imaging to investigate tumor targeting:
[0135] When the tumor volume of mice reached 200mm 3 The preparation containing Cy5.5-labeled plasmid was injected into the tail vein at 1, 4, 8, 12, 24, and 36 hours after administration. The mice were anesthetized and placed in a living imaging instrument to collect images. The results showed that the tumor microenvironment-responsive dual-targeted gene delivery system can effectively accumulate in the tumor site ( Figure 5 ).
[0136] 2. Flow cytometry to examine the uptake of the preparation by target cells:
[0137] When the tumor volume of mice reached 200mm 3 At 14:00 pm, the preparation containing DiYO-1 marker plasmid was injected into the tail vein. After 12 hours, the tumor tissue was dissected out and lysed to obtain a single cell suspension, which was then stained, washed, filtered, and transferred to a flow tube for detection. Figure 6 The results showed that the preparation was mainly taken up by two target cells: T cells and tumor cells.
[0138] 4. Flow cytometry to investigate the effect of LSD1 knockout in tumor cells and T cells
[0139] MFC gastric cancer cells were cultured and inoculated subcutaneously into 615 mice. When the tumor volume reached 100 mm3, the drug was administered once every three days for a total of five times. The tumor tissue of the tumor-bearing mice was extracted and a single cell suspension was obtained. After staining, washing, filtering, the suspension was transferred to a flow tube and detected by flow cytometry. Figure 7 AB found that LSD1 was effectively knocked out in both tumor cells and T cells.
[0140] 5. Flow cytometry to investigate the infiltration effect of CD8+ T cells and the expression of their exhaustion markers in tumor tissues
[0141] After administration, the tumor tissue of the tumor-bearing mice was extracted and a single cell suspension was obtained. After staining, washing, and filtering, the suspension was transferred to a flow tube and detected using a flow cytometer. Figure 8 AD results showed that after treatment with the dual-targeted gene delivery system, CD8 + The infiltration rate of T cells was significantly increased, and the exhaustion markers were significantly reduced.
[0142] The present invention has carried out the same experiments on other embodiments according to the above experimental method, and has obtained the same or similar results, which will not be listed one by one here.
[0143] It can be seen from the above experiments that compared with the prior art, the present invention has the following outstanding beneficial technical effects:
[0144] 1) The tumor microenvironment-responsive dual-targeted gene delivery system provided by the present invention has excellent biocompatibility and stability, and can program tumor cells and T cells in situ to exert immunotherapy;
[0145] 2) The tumor microenvironment-responsive dual-targeted gene delivery system provided by the present invention has sensitive tumor microenvironment acid responsiveness and can effectively knock out LSD1 in tumor cells and T cells in vitro and in vivo, thereby promoting CD8 + T cell infiltration, reducing the intensity of the PD-1 / PD-L1 axis, and reversing CD8 + Depletion of T cells.
[0146] The invention is easy to operate, the method is stable and reliable, the prepared tumor microenvironment responsive dual-targeted gene delivery system has good biocompatibility, can realize the particle size change from large to small under the action of acidic pH in the tumor microenvironment, separate targeting, enhance the delivery of LSD1 gene by nanoparticles to tumor cells and T cells, effectively restore the function of effector T cells, and enhance the anti-tumor immunotherapy effect. It is an innovation in in situ reprogramming cells, has practical clinical significance and good application and promotion value, and has huge economic and social benefits.
[0147] It should be pointed out that the above is only a preferred embodiment of the present invention and does not limit the present invention in any form. Any technician familiar with the profession can make changes or modify the technical contents disclosed above into equivalent embodiments with equivalent changes without departing from the scope of the technical solution of the present invention, which all fall within the protection scope of the present invention.
Claims
1. A method for preparing a tumor microenvironment responsive dual-targeting gene delivery system, characterized in that: Polyethyleneimine and 1H-pyrazole-1-carboxamidine hydrochloride are reacted at room temperature, and then the tumor cell targeting peptide and the T cell targeting peptide are modified by amide reaction, respectively, and then condensed with the sgLSD1 plasmid, respectively, and then physically mixed, glutaraldehyde is added for cross-linking, and finally poly (2-ethyl-2-oxazoline) is wrapped in the outer layer to form a stable core-shell structure to obtain a tumor microenvironment responsive dual-targeting gene delivery system.
2. The method for preparing the tumor microenvironment responsive dual-targeting gene delivery system according to claim 1, characterized in that: The specific steps include: 1) Preparation of guanidinized polyethyleneimine Take 1-6g of polyethyleneimine and dissolve it in 3-8mL of solvent, add it to a three-necked flask and protect it with nitrogen, take 1-6g of 1H-pyrazole-1-carboxamidine hydrochloride and dissolve it in 5mL of solvent, add it to the polyethyleneimine solution, stir and react at room temperature for 10-35min, add 1-6g of triethylamine to the above mixed solution, stir at room temperature for 24h, put the solution after the reaction into a 500Da dialysis bag, dialyze for 48h, and then freeze-dry the product to obtain guanidinium polyethyleneimine; 2) Preparation of T cell targeting vector 10-60 mg of T cell targeting peptide was dissolved in 1-6 mL of solvent and placed in a three-necked flask, which was filled with nitrogen for protection. 3-8 mg of N-hydroxysuccinimide and 6-11 mg of (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) were dissolved in 1 mL of solvent and added to the above three-necked flask, and stirred at room temperature for 12 h. 20-70 mg of guanidated polyethyleneimine was added to 2-7 mL of solvent to fully dissolve, and then added to the three-necked flask. After stirring at room temperature for reaction for 24 h, it was placed in a 1500 Da dialysis bag and dialyzed for 48 h to fully remove unreacted substances. The dialyzed product was freeze-dried for 48 h to obtain a T cell targeting vector. The T cell targeting peptide is a polypeptide chain containing the sequence AKMGEGGWGANDY; 3) Preparation of tumor cell targeting vector Take 20-70 mg of tumor cell targeting peptide and dissolve it in 3 mL of solvent, then add it to a three-necked flask and fill it with nitrogen for protection. Then add a solvent solution containing 3-8 mg of N-hydroxysuccinimide and 8-13 mg of (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) to the three-necked flask, activate the carboxyl group at room temperature for 12 hours, and finally add a solvent solution containing 30-80 mg of guanidinized polyethyleneimine to the above reaction system, react at room temperature for 24 hours, and the solution after the reaction is placed in a 2500Da dialysis bag for 48 hours. The product is freeze-dried for 48 hours to obtain a tumor cell targeting vector; The tumor cell targeting peptide is a polypeptide chain containing the sequence SGQYASYHCWCWRDPGRSGGSK; 4) Prepare T cell targeting vector solution and tumor cell targeting vector solution Take 30-80 mg of the T cell targeting vector prepared in step 2) and the tumor cell targeting vector prepared in step 3) and dissolve them in 40 mL of solvent respectively, adjust the pH of the above two solutions to 7.4 with 1 mol / L NaOH solution, then transfer them to a 50 mL volumetric flask, dilute to 50 mL with solvent, shake well to obtain a T cell targeting vector solution and a tumor cell targeting vector solution with a concentration of 1 mg / mL, and filter the prepared solutions with a 0.22 μm microporous filter membrane; 5) Synthesis of T cell targeting vector / plasmid complexes and tumor cell targeting vector / plasmid complexes Take two portions of plasmid, 4-9 mL and 7-12 mg respectively, dilute them to 0.01 mg / mL with a solvent, take 50 mL of the T cell targeting vector solution and the tumor cell targeting vector solution prepared in step 4), dilute them to 0.1 mg / mL with a solvent, add them dropwise to the diluted plasmid solution, shake and mix continuously, and let stand at room temperature for 10 min to obtain a T cell targeting vector / plasmid complex and a tumor cell targeting vector / plasmid complex; 6) Tumor microenvironment-responsive dual-targeted gene delivery system Take the T cell targeting vector / plasmid complex and the tumor cell targeting vector / plasmid complex in step 5), mix the two solutions in equal amounts, add 170-220 mL of 25% glutaraldehyde solution, mix well and let stand at room temperature for 5 minutes, take 30-80 mg of poly(2-ethyl-2-oxazoline) and prepare it with a solvent to a solution with a concentration of 1 mg / mL, measure 300-800 mL and add it dropwise to the above solution, let stand at room temperature for 10 minutes, and obtain a tumor microenvironment responsive dual-targeting gene delivery system.
3. The method for preparing the tumor microenvironment responsive dual-targeting gene delivery system according to claim 2, characterized in that: The specific steps include: The solvent in steps 1)-6) is one of ultrapure water, PBS buffer with pH=7.4, and formamide.
4. Use of the tumor microenvironment responsive dual-targeting gene delivery system prepared by the preparation method according to any one of claims 1 to 3 in the preparation of anti-tumor drugs.
5. Use of the tumor microenvironment responsive dual-targeting gene delivery system prepared by any one of the preparation methods of claims 1 to 3 in the preparation of highly efficient gene delivery.
